A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Trial Details

NCT ID

NCT06361888

Phase

PHASE2 / PHASE3

Sponsor

Hutchmed

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
• Nab-paclitaxel Plus Gemcitabine
• Surufatinib with Nab-paclitaxel, and Gemcitabine

Locations (sample)

• Nanjing, Jiangsu, China|32.06167,118.77778
• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• Fully understand and voluntarily sign an informed consent form, willing and able to follow the study process;
• Age range is 18-75 years old (inclusive);
• Pancreatic cancer confirmed by histology or cytology;
• Stage IV metastasis Pancreatic cancer patients;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.